Recognizing that Evidence is Made, not Born-Reference-Cited by-同舟云学术

Recognizing that Evidence is Made, not Born

Published:2019-01-04 Issue:4 Volume:105 Page:844-856
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Lim Robyn¹,Lee David K.¹,Sabourin Pierre¹,Ferguson John²,Metcalf Marilyn³,Smith Meredith⁴,Corriol‐Rohou Solange⁵,Eichler Hans‐Georg⁶,Lumpkin Murray⁷,Hirsch Gigi⁸,Chen Inhua Muijrers⁹,O'Rourke Brian¹⁰,Schiel Anja¹¹,Crabb Nick¹²,Aronson Naomi¹³,Pezalla Edmund¹⁴,Boutin Marc¹⁵,Binder Louise¹⁶,Wilhelm Linda¹⁷

Affiliation:

1. Health Products and Food BranchHealth Canada Ottawa Ontario Canada

2. Sanofi‐Aventis SA Cambridge Massachusetts USA

3. GlaxoSmithKline (GSK) Research Triangle Park North Carolina USA

4. Amgen Thousand Oaks California USA

5. AstraZeneca Paris France

6. European Medicines Agency London UK

7. Bill and Melinda Gates Foundation Seattle Washington USA

8. MIT Center for Biomedical InnovationNEWDIGS Cambridge Massachusetts USA

9. C&C Healthcare Consulting LLC Durham North Carolina USA

10. Canadian Agency for Drugs and Technologies in Health Ottawa Ontario Canada

11. HTA DivisionNorwegian Medicines Agency Oslo Norway

12. NICE Manchester UK

13. Blue Cross Blue Shield Association Chicago Illinois USA

14. Enlightenment Bioconsult LLC Wethersfield Connecticut USA

15. National Health Council Washington District of Columbia USA

16. Save Your Skin Foundation North Vancouver British Columbia Canada

17. Canadian Arthritis Patient Alliance Midland New Brunswick Canada

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1317

Reference125 articles.

1. Estimation of clinical trial success rates and related parameters;Wong C.H.;Biostatistics,2018

2. Thomas D.W. Burns J. Audette J. Carrol A. Dow‐Hygelund C.&Hay M.Clinical development success rates 2006–2015. BIO Biomedtracker Amplion San Diego (2016). . Accessed February 20 2018.

3. Innovation in the pharmaceutical industry: New estimates of R&D costs

4. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

5. The High Cost of Prescription Drugs in the United States

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are Global Health Systems Ready for Transformative Therapies?;Value in Health;2019-06

2. Regulation and Innovation: Role of Regulatory Science in Facilitating Pharmaceutical Innovation;Clinical Pharmacology & Therapeutics;2019-03-18